E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with Angina pectoris having been treated by Percutaneous Coronary Intervention |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with angina having been treated by dilatation of coronary arteries. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10002383 |
E.1.2 | Term | Angina pectoris |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Demonstrate the superiority of trimetazidine over placebo in preventin recurrence or exacerbation of angina pectoris and reducing cardiac events, and to document its safety by analysing the occurrence of serious adverse events |
|
E.2.2 | Secondary objectives of the trial |
Evaluate the effect of trimetazidine on the other efficacy endpoints as well as the other safety parameters, clinical and biological |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Women or men ≥ 21 years old and < 85 years old of any ethnic origin
Patients presenting a single or multivessel coronary artery disease and having undergone PCI treating at least one stenosis to either a native coronary artery or a coronary graft where the PCI was:
- indicated because of angina pectoris occurring either in the context of stable angina (elective PCI) or in the context of an acute presentation such as unstable angina/NSTEMI, but excluding STEMI,
- achieved by stent implantation or by other acceptable interventional means,
- successful as planned by the operator and with no further revascularization (either percutaneous or surgical) planned,
- uncomplicated such that the patient's discharge was not, or will not be, delayed because of a cardiac or cerebrovascular problem |
|
E.4 | Principal exclusion criteria |
- Severe uncontrolled rythm disturbances including paroxysmal VT and SVT
- Kown severe aortic or mitral valve disease
- Clinical signs and/or symptoms of heart failure corresponding to NYHA class IV
- Hypertrophic obstructive cardiomyopathy or other forms of left ventricular outflow tract obstruction
- Active myocarditis, pericarditis or endocarditis
- Hystory of agranulocytosis, severe thrombocytopenia or severe coagulation disorder
- History of pulmonary embolism within preceding 6 months
- Known severe uncontrolled arterial hypertension
- Known chronic severe or moderate renal failure, with sCrCl < 60 mL/min or eGFR<60 mL/min/1.73m2
- Current or previous movement disorders such as Parkinsonian symptoms, restless leg syndrome, tremor, gait instability of central origin |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time to first occurrence of an event in the composite of:
- Cardiac death
- Hospitalisation for a cardiac event
- Recurrent or persistent angina leading to adding, switching or increasing the dose of one of the evidence-based antianginal therapies
- Recurrent or persistent angina leading to performing a coronary angiography |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary efficacy endpoints and safety |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 305 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Serbia |
Algeria |
Armenia |
Austria |
Belarus |
Brazil |
Bulgaria |
Chile |
China |
Colombia |
Croatia |
Denmark |
Estonia |
France |
Georgia |
Germany |
Greece |
Hungary |
Indonesia |
Italy |
Jordan |
Kazakhstan |
Korea, Republic of |
Latvia |
Lebanon |
Lithuania |
Malaysia |
Montenegro |
Morocco |
Netherlands |
Portugal |
Spain |
Thailand |
Macedonia, the former Yugoslav Republic of |
Mexico |
Peru |
Philippines |
Poland |
Romania |
Russian Federation |
Singapore |
Slovakia |
Slovenia |
South Africa |
Switzerland |
Tunisia |
Turkey |
Ukraine |
Vietnam |
Argentina |
Bosnia and Herzegovina |
Canada |
Czech Republic |
Egypt |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last Visit Last Participant as stated in the protocol |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |